- Home
- CUE vs CULP Comparison
CUE vs CULP Comparison
Compare CUE & CULP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | CULP |
|---|---|---|
| Founded | 2014 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Textiles |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 43.8M |
| IPO Year | 2017 | 1994 |
Fundamental Metrics
Financial Performance| Metric | CUE | CULP |
|---|---|---|
| Price | $0.31 | $3.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 316.8K | 20.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.14 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $9,287,000.00 | ★ $213,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.00 | $6.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 69.16 | N/A |
| 52 Week Low | $0.23 | $3.13 |
| 52 Week High | $1.12 | $5.64 |
Technical Indicators
Market Signals| Indicator | CUE | CULP |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 32.63 |
| Support Level | $0.26 | N/A |
| Resistance Level | $0.36 | $3.64 |
| Average True Range (ATR) | 0.02 | 0.17 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 63.18 | 2.51 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About CULP Culp Inc.
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.